AlphaFold-based structural analysis highlighted a helix-helix-turn-helix subdomain in PHGDH that resembles a TALE homeodomain, prompting tests of a previously unrecognized DNA-binding and transcriptional function. Experiments supported PHGDH binding to promoters and activation of IKKα and HMGB1 in astrocytes, independently of its metabolic enzyme activity. In mouse models and human brain organoids, PHGDH expression promoted amyloid pathology; a blood-brain-barrier-permeable inhibitor of its transcriptional function reduced amyloid pathology and improved measured behavioral deficits in mice.
Technology: AlphaFold structure prediction, followed by structural comparison of the predicted PHGDH fold
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: AlphaFold-based structural analysis highlighted a helix-helix-turn-helix subdomain in PHGDH that resembles a TALE homeodomain, prompting tests of a previously unrecognized DNA-binding and transcriptional function.
- Still unknown: The AlphaFold-derived structural resemblance generated the mechanistic hypothesis; experiments establish the reported PHGDH transcriptional and pathology effects in the tested models. The inhibitor and behavioral effects were tested in mice, not people. Human brain organoid findings are in vitro and do not establish clinical disease causation or treatment efficacy. PHGDH overexpression alone did not reproduce all Alzheimer’s disease features, and no human therapeutic outcome is reported.
- AI role: The researchers inspected AlphaFold-predicted PHGDH structure and identified a helix-helix-turn-helix subdomain resembling a TALE homeodomain, which motivated the hypothesis and targeted mutation tests for DNA binding. AlphaFold did not establish PHGDH function or disease causality; the transcriptional activity and pathology effects were tested through biochemical, cellular, organoid and mouse experiments.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12204802/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 20 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Models trained on promoter activity measurements helped characterize a human-specific downstream promoter variant and select synthetic motifs with species-specific activity. In-vitro transcription assays tested the predicted preferences with human and Drosophila extracts. These are gene-regulation and construct-assay findings, not demonstrated effects in organisms or disease.
Technology: HARPE-trained support-vector regression
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Predicted promoter preferences were compared with measured transcription in extracts.
- Still unknown: Native-chromatin regulatory effects and organism-level outcomes were not established.
- AI role: HARPE-trained support-vector regression supported the stated study; experimental and interpretive work remained with researchers.
Evidence sources: https://escholarship.org/uc/item/1rt3r053 · https://escholarship.org/content/qt1rt3r053/qt1rt3r053.pdf · https://pubmed.ncbi.nlm.nih.gov/37163335/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Institutional manuscript abstract and selected SVR Methods; primary PubMed early-online date, affiliations and experimental figure captions..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
COMPOSER, a deep-learning early sepsis predictor, reached AUCs of 0.925-0.953 in ICU and 0.938-0.945 in ED across six cohorts (515,720 patients) from two US health systems. About 20% of non-septic and 8% of septic prediction windows were marked indeterminate, and the model gave a median early warning of 12.2 hours in ICU and 2.1 hours in ED before the first antibiotics order. The abstract reports no prospective deployment or patient-outcome results.
Technology: COMPOSER deep-learning model with uncertainty-based indeterminate output
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: COMPOSER's AUCs were measured across six cohorts (515,720 patients) from two US health systems in ICU and ED settings, with the share of predictions marked indeterminate and early-warning time before the first antibiotics order.
- Still unknown: The abstract reports no prospective deployment or patient-outcome results; data come from only two US health systems.
- AI role: A deep-learning model predicted early sepsis and marked unfamiliar cases as indeterminate rather than guessing.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41746-021-00504-6&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 147 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Learning from transcriptomic networks helped prioritize PRKAB1 for experimental follow-up. An agonist improved a barrier-resistance endpoint in about 80% of diseased patient-derived organoids in the tested sample. This is preclinical target-response evidence, not treatment of patients or clinical efficacy. The network direction incorporates sample labels and does not independently establish causal disease progression.
Technology: Boolean Network Explorer learned implication networks
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Patient-derived organoid barriers and preclinical models were tested.
- Still unknown: Clinical safety and benefit, independent replication and causal network direction remain unestablished.
- AI role: Boolean Network Explorer learned implication networks supported the stated study; experimental and interpretive work remained with researchers.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8275683/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary article metadata, affiliations, selected network Methods and organoid Results; supplements not reviewed..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A Bayesian optimization workflow using symmetry-constrained crystal relaxation and the MEGNet graph neural network screened 399,960 transition-metal boride and carbide compositions. The study identified MoWC₂ (P6₃/mmc) and ReWB (Pca2₁), then synthesized both by in-situ reactive spark-plasma sintering; the measured hardness was reported to agree with model and DFT predictions. The result is limited to these two synthesized compounds and the authors’ tested synthesis conditions.
Technology: BOWSR (Bayesian Optimization With Symmetry Relaxation) with the MEGNet graph neural network energy model
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: A Bayesian optimization workflow using symmetry-constrained crystal relaxation and the MEGNet graph neural network screened 399,960 transition-metal boride and carbide compositions.
- Still unknown: The arXiv abstract states that the two materials were synthesized and describes them as ultra-incompressible hard materials; the institutional project page reports experiments on eight selected candidates and confirmation of two novel hard materials. The result is from a preprint/journal study and the provided abstract does not give numeric hardness values. Do not imply commercial performance or broader synthesis robustness.
- AI role: MEGNet supplied graph-based formation-energy predictions; BOWSR used Bayesian optimization under crystal-symmetry constraints to relax candidate structures without DFT geometry relaxation. This enabled screening of 399,960 boride/carbide compositions, narrowing candidates for experimental synthesis.
Evidence sources: https://arxiv.org/abs/2104.10242
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 153 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A random-forest model ranked new chromium-containing multicomponent carbide compositions by predicted entropy-forming ability. After density-functional calculations and experimental synthesis, X-ray diffraction identified four previously unreported single-phase rock-salt compositions: CrMoNbVWC₅, CrMoNbTaWC₅, CrMoTaVWC₅, and CrMoTiVWC₅. The first three were high-EFA selections; CrMoTiVWC₅ was a medium-EFA composition and required extended annealing to reach chemical homogeneity.
Technology: Random-forest models using chemical attributes, with and without CALPHAD thermodynamic features
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: A random-forest model ranked new chromium-containing multicomponent carbide compositions by predicted entropy-forming ability.
- Still unknown: Only seven of the 70 model-screened candidates were selected for DFT and synthesis, and several tested compositions formed multiple phases. Single-phase identification used XRD and was supported by microstructure, elemental mapping and EBSD; the medium-EFA CrMoTiVWC₅ sample required extended annealing. The paper establishes synthesis and phase formation, not measured application performance or engineering readiness.
- AI role: The random-forest models learned entropy-forming ability from 56 previously reported carbide compositions and rapidly screened 70 new chromium-containing candidates. Model rankings guided selection of seven compositions for DFT calculations and synthesis; experimental phase outcomes agreed with predicted rankings, including four single-phase materials.
Evidence sources: https://www.nature.com/articles/s41524-020-0317-6
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 288 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An interpretable machine-learning model integrated transcriptomic, epigenomic, metabolomic and proteomic data from Huntington-disease cell models to identify previously unknown mechanisms for protective compounds. The analysis predicted autophagy activation for one compound group and mitochondrial-respiration inhibition for another; follow-up imaging, biochemical and energetics assays experimentally confirmed these effects in the cell model.
Technology: Interpretable network-optimization model integrating multi-omics over a molecular-interaction network
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The analysis predicted autophagy activation for one compound group and mitochondrial-respiration inhibition for another; follow-up imaging, biochemical and energetics assays experimentally confirmed these effects in the cell model.
- Still unknown: Findings were experimentally established in STHdhQ111 murine striatal cells, with autophagy effects also checked in human SH-SY5Y and HEK293 cell lines. The paper notes that the model prioritizes pathways but does not resolve every causal step or demonstrate therapeutic efficacy in patients.
- AI role: The model integrated multiple omics and prioritized cellular pathways as candidate mechanisms of action; researchers tested those predictions with cellular imaging, biochemical assays and energetics measurements. It revealed unexpected mechanisms for compounds with unrelated known targets.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC6976599/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 76 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.